FDA adds warning for rare eye disorder linked to GLP-1 medicines
Ozempic, Wegovy and similar medicines will carry a warning in the United States about possible permanent loss of vision.
The US regulator FDA is requiring manufacturers of GLP-1 medicines to warn about a rare eye disorder. NAION can cause sudden and sometimes permanent loss of vision in one eye.
The FDA announced the change on Monday after analysing more than 125 clinical trials. According to the regulator, the condition occurred in approximately six out of every 100,000 patients who used a GLP-1 medicine and were followed for at least a year.
NAION stands for non-arteritic anterior ischaemic optic neuropathy. According to the FDA, the condition can lead to sudden and sometimes permanent loss of vision in one eye. The FDA stresses that it is a rare side effect.
The new warning applies to several medicines in the GLP-1 group, including semaglutide products such as Ozempic and Wegovy. Other medicines in the group will also receive updated safety information, according to the FDA. The measure does not automatically change the treatment choice for every patient.
The FDA bases the warning on an analysis of clinical data, but a warning on the label does not mean that every user faces an increased risk or that the medicines cause the condition in all users. It is a signal that, according to the regulator, should be included in the product information.
In Europe, the safety information for semaglutide was already amended earlier to include information about NAION. The US move is putting the issue in the spotlight again because the medicines are widely used there for diabetes and weight loss.
For patients, the most important point is that sudden changes in vision should be medically assessed. This article is not personal treatment advice: people using a GLP-1 medicine should discuss questions about their own medication with their doctor or pharmacist and should not stop taking it on their own.
The main qualification concerns the balance between severity and likelihood. Permanent loss of vision can be serious, but the FDA estimates that the reported condition is very rare. The new warning makes the risk more visible without proving that the medicine is unsafe for every user.
Also show the region and a close-up
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The safety measure, the condition and the estimated frequency were directly checked with the FDA and AP. The text distinguishes between a warning about a possible risk and proven causality in every user.
- confirmed The FDA is requiring new warnings for GLP-1 medicines. — The FDA published a Drug Safety Communication on this on 9 November 2026. source
- confirmed The analysis covered more than 125 clinical trials. — This is stated in the FDA communication and summarised by AP. source
- confirmed The condition occurred in approximately six out of every 100,000 patients per year. — AP cites the FDA estimate of approximately six cases per 100,000 patients followed for at least a year. source
- confirmed NAION can cause sudden and permanent loss of vision in one eye. — The FDA describes NAION as a rare condition that can cause acute and sometimes permanent loss of vision. source
- confirmed The European product information for Ozempic mentions NAION. — The EMA product information includes this side effect. source
Editor's note
The FDA warning and the estimated frequency have been confirmed. It concerns a rare possible side effect; the sources do not justify a general conclusion that GLP-1 medicines are unsafe for all users.Sources
- FDA Requires Safety Labeling Changes for GLP-1 Receptor Agonists — U.S. Food and Drug Administration
- FDA adds rare vision-loss warning to popular GLP-1 drugs — AP
- Ozempic product information — European Medicines Agency
More on this in Dutch media
- NOS — „fda ozempic”
- Het Parool — „fda ozempic”
- Trouw — „fda ozempic”